Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Rating of “Buy” from Analysts

Aquestive Therapeutics, Inc. (NASDAQ:AQST) has earned a consensus recommendation of “Buy” from the eight research firms that are covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $10.57.

Several research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Monday, March 10th. Alliance Global Partners restated a “buy” rating on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Lake Street Capital reduced their price objective on Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, March 7th. Cantor Fitzgerald assumed coverage on Aquestive Therapeutics in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 price objective on the stock. Finally, Raymond James set a $7.00 price target on Aquestive Therapeutics in a report on Friday, March 7th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in shares of Aquestive Therapeutics by 1.9% during the 4th quarter. Vanguard Group Inc. now owns 4,346,754 shares of the company’s stock worth $15,474,000 after purchasing an additional 82,958 shares during the period. Geode Capital Management LLC lifted its stake in Aquestive Therapeutics by 5.7% in the third quarter. Geode Capital Management LLC now owns 1,667,515 shares of the company’s stock worth $8,306,000 after purchasing an additional 90,543 shares during the last quarter. State Street Corp boosted its position in shares of Aquestive Therapeutics by 52.1% during the third quarter. State Street Corp now owns 1,496,739 shares of the company’s stock valued at $7,454,000 after buying an additional 512,682 shares during the period. Janney Montgomery Scott LLC grew its stake in shares of Aquestive Therapeutics by 6.6% during the fourth quarter. Janney Montgomery Scott LLC now owns 984,485 shares of the company’s stock valued at $3,505,000 after buying an additional 61,200 shares during the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of Aquestive Therapeutics by 905.2% in the fourth quarter. Bank of America Corp DE now owns 690,284 shares of the company’s stock worth $2,457,000 after buying an additional 621,614 shares during the period. 32.45% of the stock is owned by hedge funds and other institutional investors.

Aquestive Therapeutics Stock Down 5.9 %

AQST opened at $3.02 on Monday. The business has a 50 day moving average of $2.99 and a 200-day moving average of $3.94. The stock has a market cap of $298.59 million, a price-to-earnings ratio of -6.71 and a beta of 2.76. Aquestive Therapeutics has a 12-month low of $2.24 and a 12-month high of $5.80.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The business had revenue of $11.87 million during the quarter, compared to analysts’ expectations of $13.11 million. As a group, analysts expect that Aquestive Therapeutics will post -0.46 earnings per share for the current year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.